Home  >  About Us

About Us

Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was incorporated by the Manipal Group in Jan 2006 and entered into a strategic alliance with Cipla in 2009. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team. Currently it is focusing on the following three innovative products:

Company's flagship product is Stempeucel®. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from bone marrow of healthy, adult volunteers. Stempeucel® is being developed for the treatment of Critical Limb Ischemia (CLI) due to Buerger's disease amongst other indications such as Osteoarthritis (OA) & Liver Cirrhosis (LC). In 2016 DCGI (Indian FDA) granted limited marketing approval for treatment of CLI patients due to Buerger's disease. Stempeucel® has strong patent protection with 18 patent applications filed across the globe. These patents create a strong barrier to entry for the development of alternative pooled allogeneic stem cell products by competitors. The core Stempeucel® patent has been granted in USA, Australia, New Zealand, South Africa, Japan, China and Singapore. Stempeucel® has been classified as an ATMP product by EMA and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by EMA

The second product Stempeutics is developing is Stempeutron™ medical device. It is a point-of-care, closed system, automated medical device for the isolation of stromal vascular fraction (SVF) cells from human adipose tissue for addressing the need in the broad field of regenerative medicine. Stempeutron is the first product to use novel robotic and filtration technology to isolate clinical grade SVF from adipose tissue. SVF has broad clinical utility in regenerative medicine for repair of diseased organs as well as in plastic and reconstructive surgery.

The third innovative product Stempeutics has developed is Stempeucare™. It is an intensive firming skin care cosmetic product, branded as Cutisera™. Cutisera™ product has 5 distinct benefits i.e. (1) reduction of lines and wrinkles (2) reduction / lightning of dark spots (3) evenness of skin tone (4) improvement in skin firmness (5) Improvement in skin hydration. It is developed from adult stem cells derived growth factors/Cytokines cocktail to enhance the rejuvenation of aging skin. Cutisera™ has been launched in India in December 2015

Scientists working at Stempeutics have filed over 65 patents and have published over 60 peer reviewed international publications. Stempeutics is committed to deliver safe, effective and affordable stem cell products in a "Bench to Bedside" approach.

 

   

The company's lead product Stempeucel®, is ex-vivo cultured adult allogeneic mesenchymal stromal cells derived by using a novel pooling technology from multiple bone marrow donors and can be used as an 'off-the-shelf' cryopreserved stem cell product.
FIRST stem cell based biological product to be approved by DCGI for limited sales

 

It is an intensive firming skin care cosmetic product, branded as Cutisera. Cutisera product has 5 distinct benefits i.e.
  (1) reduction of lines and wrinkles
  (2) reduction / lightning of dark spots
  (3) evenness of skin tone
  (4) improvement in skin firmness
  (5) Improvement in skin hydration.

 

It is an automated, point-of-care medical device for isolation of therapeutic stem and stromal cells from aspirated fat/adipose tissue. Adipose tissue stroma is a rich source of mesenchymal stem cells and endothelial progenitor cells, as well as other tissue-building cells such as vascular smooth muscle cells, pericytes, pre-adipocytes and fibroblasts.